on OXURION (EBR:OXUR)
Oxurion to Acquire Preclinical Microbiology CRO in Toulouse
Oxurion NV, a biopharmaceutical company, has signed a letter of intent to acquire 70% of a preclinical microbiology company specializing in infectious diseases, dermocosmetics, and nutraceuticals. This acquisition aligns with Oxurion's strategy to diversify its expertise and strengthen its presence in Toulouse.
The target company has been a leader in preclinical services for over a decade, providing research and development services in human and animal infectious diseases. It has also expanded into high-growth sectors like dermocosmetics and nutraceuticals, serving over 140 clients globally.
The acquisition is valued at €750,000. Initial payment will be €525,000, with potential earn-outs based on performance. Oxurion aims to complete the transaction by October 2025, pending due diligence and legal agreements.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news